Catalent, a service provider for biopharma, cell, gene, and consumer health partners, has announced plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies, and increase its secondary packaging capabilities.
The site will be expanded by approximately 30,000 sqft, doubling its clinical storage capacity and facilitating the installation of additional refrigerated and deep-frozen storage. Both expansion and commissioning are expected to be complete by mid-2022, the company says.
“We have seen great demand for clinical supply services in China from international sponsors looking to conduct trials in the region and seeking Catalent’s experience in providing reliable, flexible, and integrated support,” said Roel de Nobel, Catalent’s VP and General Manager, APAC, Clinical Supply Services.
“This expansion will increase both capacity and capabilities at the Shanghai FTZ facility, and makes provision for the growing trend in clinical trials of advanced therapeutics requiring specialised storage and handling capabilities, including deep-frozen for emerging biotech companies.”
